Stoke Therapeutics (STOK) EBT Margin (2022 - 2026)
Stoke Therapeutics' (STOK) quarterly EBT Margin came in at 802.75% in Q1 2026, down 87474.0% year-on-year from N/an in Q1 2025, and up 81.97% quarter-over-quarter from 4453.35% in Q4 2025.
Stoke Therapeutics (STOK) EBT Margin (2022 - 2026) Analysis & Trends
Stoke Therapeutics' EBT Margin history runs 5 years deep, the most recent figure standing at 802.75% for Q1 2026.
- On a quarterly basis, EBT Margin fell 87474.0% year-over-year to 802.75% in Q1 2026; TTM through Mar 2026 was 547.22%, a 57199.0% decrease from a year earlier, with the FY2025 full-year figure at 110.77%, up 22276.0% from the prior year.
- EBT Margin rose to 802.75% in Q1 2026 per STOK's latest filing, from 4453.35% in the prior quarter.
- Across five years, EBT Margin topped out at 71.99% in Q1 2025 and bottomed at 5809.03% in Q4 2023.
- The 5-year median for EBT Margin is 802.75% (2026), against an average of 1339.78%.
- Across the five-year window, EBT Margin surged 574384 bps in 2024 and tumbled 438816 bps in 2025, its largest moves.
- Year by year, EBT Margin stood at 3811.14% in 2022, then slumped by 52 bps to 5809.03% in 2023, then jumped by 99 bps to 65.19% in 2024, then tumbled by 6731 bps to 4453.35% in 2025, then surged by 82 bps to 802.75% in 2026.
- Per Business Quant, the three latest STOK EBT Margin figures stand at 802.75% (Q1 2026), 4453.35% (Q4 2025), and 372.7% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Stoke Therapeutics | 1.87 Bn | 1.53 Bn | - | -802.75% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -802.75% |
| Dec 31, 2025 | -4,453.35% |
| Sep 30, 2025 | -372.70% |
| Jun 30, 2025 | -169.96% |
| Mar 31, 2025 | 71.99% |
| Dec 31, 2024 | -65.19% |
| Sep 30, 2024 | -540.05% |
| Jun 30, 2024 | -531.88% |
| Mar 31, 2024 | -625.57% |
| Dec 31, 2023 | -5,809.03% |
| Sep 30, 2023 | -821.46% |
| Jun 30, 2023 | -1,495.04% |
| Mar 31, 2023 | -479.64% |
| Dec 31, 2022 | -3,811.14% |
| Sep 30, 2022 | -1,007.85% |
| Jun 30, 2022 | -996.16% |
| Mar 31, 2022 | -866.50% |